Compare Abbott Laboratories (ABT) vs Figs Inc (FIGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Figs Inc — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while Figs Inc trades at $10.29 (market cap $1.65B). The key difference: Abbott Laboratories is far larger — about 101.2× Figs Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Figs Inc pays none. Which is the better fit depends on your goals.
| ABT | FIGS | |
|---|---|---|
Market Cap | $166.94B | $1.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $17.12 |
52-Week Low | $82.57 | $5.81 |
Enterprise Value | $193.69B | $1.44B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
FIGS stock trades at $9.90, down 0.9% today, with a mixed technical picture showing a bearish moving average trend but oversold RSI levels. The company reported strong Q1 2026 earnings, beating estimates with 28% revenue growth and raised full-year guidance. Analyst consensus is a Buy with a $18.00 price target, implying significant upside, though valuation ratios like a P/E of 44.91 remain elevated.
The outlook is cautiously optimistic, driven by robust revenue growth, expanding margins, and global expansion. Key risks include cost pressures from tariffs and freight, competitive threats, and the stock's high valuation requiring sustained execution. Near-term performance hinges on Q2 2026 earnings delivery against a $0.07 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
